Literature DB >> 10707011

Lymphatic transport of proteins after subcutaneous administration.

C J Porter1, S A Charman.   

Abstract

This mini-review summarizes the relevant literature regarding the lymphatic transport of proteins after subcutaneous administration. A review of the physiology of the lymphatics and inherent anatomical differences between blood and lymph capillaries is presented followed by a brief overview of the general characteristics of protein absorption and bioavailability following S.C. injection. A description of factors known to directly affect the lymphatic uptake of macromolecules follows and is supported by representative data from this laboratory. A brief perspective on the importance of lymphatic uptake and transport in understanding the biopharmaceutical properties of protein drugs and potentially targeting the lymphatics is presented.

Mesh:

Substances:

Year:  2000        PMID: 10707011     DOI: 10.1002/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  62 in total

1.  Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model.

Authors:  S A Charman; D N McLennan; G A Edwards; C J Porter
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.

Authors:  Akashi Togawa; Takanori Tanaka; Satoru Nagashima; Hiroyuki Keta; Yasue Kobayashi; Yasuhiro Nishikawa; Masanobu Yanai; Hideji Tanaka
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

3.  The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.

Authors:  Danielle N McLennan; Christopher J H Porter; Glenn A Edwards; Anne C Heatherington; Steven W Martin; Susan A Charman
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

4.  Population pharmacokinetics of darbepoetin alfa in healthy subjects.

Authors:  Balaji Agoram; Liviawati Sutjandra; John T Sullivan
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

5.  Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

Authors:  Per Olsson-Gisleskog; Philippe Jacqmin; Juan Jose Perez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Mechanistic determinants of biotherapeutics absorption following SC administration.

Authors:  Wolfgang F Richter; Suraj G Bhansali; Marilyn E Morris
Journal:  AAPS J       Date:  2012-05-23       Impact factor: 4.009

Review 7.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 8.  Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.

Authors:  Anas M Fathallah; Richard B Bankert; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2013-07-16       Impact factor: 4.009

9.  In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Authors:  Vasco Filipe; Ivo Que; John F Carpenter; Clemens Löwik; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

10.  PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

Authors:  Lisa M Kaminskas; David B Ascher; Victoria M McLeod; Marco J Herold; Caroline P Le; Erica K Sloan; Christopher J H Porter
Journal:  J Control Release       Date:  2013-03-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.